Crinetics Pharmaceuticals CRNX Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $10.73M+2,873% | $6.16M— | $143K— | $1.03M+158% | $361K-43.6% | ||
| $200K— | —— | —— | —— | $0— | ||
| $10.53M+2,818% | —— | —— | —— | $361K+39.0% | ||
| 98.1%-1.9pp | —— | —— | —— | 100%+59.4pp | ||
| $100.08M+31.3% | $85.05M+27.8% | $90.46M+46.1% | $80.3M+37.6% | $76.24M+42.9% | ||
| —— | $47.83M+91.8% | $47.83M+91.8% | $47.83M+91.8% | $47.83M+91.8% | ||
| $50.83M+43.1% | —— | $52.27M+102% | $49.84M+101% | $35.53M+70.6% | ||
| $151.11M+35.2% | —— | —— | —— | $111.77M+31.5% | ||
| -$140.38M-26.0% | -$133.67M-41.1% | -$142.59M-62.4% | -$129.11M-56.0% | -$111.41M-51.5% | ||
| -1,307.8%+29,552pp | -2,169.6%— | -99,710.5%— | -12,523%+8,225pp | -30,860.1%-19,371pp | ||
| $12.66M-14.6% | $11.16M-22.4% | $12.54M+14.0% | $13.46M+53.9% | $14.83M+103% | ||
| $12.53M-14.3% | $11.03M-22.0% | $12.5M+13.9% | $13.48M+54.4% | $14.63M+107% | ||
| —— | $45K— | $45K— | $45K— | $45K— | ||
| -$127.85M-32.1% | -$122.82M-52.4% | -$130.09M-69.3% | -$115.64M-56.2% | -$96.77M-44.6% | ||
| -1,191%+25,616pp | -1,993.4%— | -90,972.7%— | -11,216%+7,344pp | -26,807.2%-16,349pp | ||
| -$1.23-18.3% | -$1.29-48.3% | -$1.38-43.7% | -$1.23-30.9% | -$1.04-11.8% | ||
| -$1.23-18.3% | -$1.29-48.3% | -$1.38-43.7% | -$1.23-30.9% | -$1.04-11.8% | ||
| 104.1M+11.8% | 94.1M+16.4% | 94.2M+17.6% | 93.8M+18.7% | 93.1M+28.8% | ||
| 104.1M+11.8% | 94.1M+16.4% | 94.2M+17.6% | 93.8M+18.7% | 93.1M+28.8% | ||
| -$130.96M-36.8% | -$123.14M-50.8% | -$129.52M-73.6% | -$116.02M-55.9% | -$95.74M-41.3% | ||
| —— | -$116.33M-56.2% | -$116.33M-56.2% | -$116.33M-56.2% | -$116.33M-56.2% | ||
| $28K+367% | -$123K— | -$21K— | -$34K— | $6K— | ||
| -$3.15M-405% | —— | $594K-73.3% | -$347K-2.1% | $1.03M+225% | ||
| -$131K+35.5% | -$125K+42.7% | -$49K-32.4% | $0— | -$203K— | ||
| $10.73M+2,873% | $6.16M— | $143K— | $1.03M+158% | $361K-43.6% | ||
| -$140.38M-26.0% | -$133.67M-41.1% | -$142.59M-62.4% | -$129.11M-56.0% | -$111.41M-51.5% | ||
| -$139.22M-26.0% | -$132.67M-41.2% | -$141.57M-62.7% | -$128.15M-56.2% | -$110.48M-51.2% | ||
| -$139.22M-26.0% | -$132.67M-41.2% | -$141.57M-62.7% | -$128.15M-56.2% | -$110.48M-51.2% | ||
| -1,297%+29,307pp | -2,153.4%— | -99,002.8%— | -12,430%+8,129pp | -30,603.9%-19,189pp | ||
| -$140.38M-26.0% | -$133.67M-41.1% | -$142.59M-62.4% | -$129.11M-56.0% | -$111.41M-51.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Crinetics Pharmaceuticals's profit margins?
- Gross margin is 150.0% and operating margin is -3020.3%, with a -2747.2% net margin.
- Where does Crinetics Pharmaceuticals's income statement data come from?
- Every line is extracted from Crinetics Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.